ArticleScientific reports2025
In vitro evaluation of Bacillus subtilis isolated from Apis mellifera for potential use as a probiotic feed additive in honeybees.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Probiotic properties ofFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The honeybee Apis mellifera plays a crucial role in global agriculture but faces significant threats from pathogens, pesticides, and nutritional stress in the beekeeping industry. In this study, we evaluate the potential application of Bacillus subtilis MBLB2796 isolated from the honeybee gut. Solid-state fermentation of soybean meal with MBLB2796 reduced allergenic proteins and anti-nutritional factors, enhancing its nutritional quality. Strain MBLB2796 also exhibited high hydrolytic enzyme activities (15.5 mm of protease, 13.5 mm of amylase, and 15.0 mm of cellulase), strong antimicrobial activity (20.5 mm) against Paenibacillus larvae, and antioxidant activity against DPPH and ABTS radicals (66.2% and 62.3%, respectively). Strain MBLB2796 demonstrated a strong survival rate after freeze-drying up to 94.4%, excellent stability during long-term storage, and superior acid and bile salt tolerance compared to commercial strains. Adhesion to Caco-2 cells was also comparable to the probiotic reference and commercial strain. Optimization of culture conditions using a one-factor-at-a-time approach identified 2.0% of yeast extract, 1.0% of galactose, and 0.25% of K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.